Life-Space Mobility and Objectively Measured Movement Behavior in Older Adults with Hypertension after Receiving COVID-19 Vaccination

Int J Environ Res Public Health. 2022 Oct 1;19(19):12532. doi: 10.3390/ijerph191912532.

Abstract

This study examined the changes in life-space (LS) mobility and objectively measured movement behavior in older adults with hypertension after receiving the COVID-19 vaccine and their associations with housing type. A total of 32 participants were included in this exploratory longitudinal study with a 1-year follow-up. LS mobility and accelerometer-based physical activity (PA) and sedentary behavior (SB) were assessed before and ~2 months after receiving COVID-19 vaccination. Participants residing in apartment/row housing showed an increase in LS mobility composite score (β = 14, p < 0.05). In addition, they showed an increase in light PA on weekdays and the weekend (β = 3.5%; β = 6.5%; p < 0.05) and a decrease in SB on weekdays and the weekend (β = -3.7%; β = -6.6%; p < 0.05). Furthermore, changes in SB pattern were found (less time spent in bouts of ≥10 and 30 min, more breaks/day and breaks/hour). Significant associations were found between changes in LS mobility composite score and PA (positive association) and SB (negative association) in older adults residing in apartment/row housing (p < 0.05). Older adults with hypertension, particularly those who resided in houses with limited outdoor space (apartment/row housing), showed positive changes in LS mobility and objectively measured movement behavior in a period after receiving the COVID-19 vaccine and characterized by social distancing policies without mobility restrictions when compared with the period of social distancing policies with high mobility restrictions and without vaccine.

Keywords: coronavirus; life-space assessment; physical activity; sedentary behavior; social distancing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Accelerometry
  • Aged
  • COVID-19 Vaccines / therapeutic use
  • COVID-19* / prevention & control
  • Humans
  • Hypertension* / epidemiology
  • Longitudinal Studies
  • Vaccination

Substances

  • COVID-19 Vaccines

Grants and funding

This study was partially supported by the Brazilian National Council for Scientific and Technological Development (CNPq; 427729/2018-1). First author is supported by a PhD scholarship from the Brazilian Coordination of Improvement of Higher Education Personnel (CAPES; 88882.375386/2019-01). Last author is supported by a research productivity grant from CNPq (306744/2019–8).